The multidrug transporter ABCG2 (BCRP) is inhibited by plant‐derived cannabinoids
- 1 November 2007
- journal article
- Published by Wiley in British Journal of Pharmacology
- Vol. 152 (5), 815-824
- https://doi.org/10.1038/sj.bjp.0707467
Abstract
Cannabinoids are used therapeutically for the palliation of the adverse side effects associated with cancer chemotherapy. However, cannabinoids also inhibit both the activity and expression of the multidrug transporter, P-glycoprotein in vitro. Here we address the interaction of cannabinol (CBN), cannabidiol (CBD) and delta 9-tetrahydrocannabinol (THC) with the related multidrug transporter, ABCG2. Cannabinoid inhibition of Abcg2/ABCG2 was assessed using flow cytometric analysis of substrate accumulation and ATPase activity assays. The cytotoxicity and chemosensitization by cannabinoids was determined with cell viability assays. Expression of cannabinoid and vanilloid receptors was assessed using reverse transcriptase polymerase chain reaction, and cannabinoid modulation of ABCG2 expression was examined using immunoblotting. CBN, CBD and THC increased the intracellular accumulation of the Abcg2/ABCG2 substrate, mitoxantrone, in an over-expressing cell line. The THC metabolite, (-)-11-nor-9-carboxy-delta 9-THC was much less potent. The plant cannabinoids inhibited both basal and substrate stimulated ATPase activity of human ABCG2. Cannabinoid cytotoxicity occurred in the absence of known cannabinoid cell surface receptors, and only at concentrations higher than those required for Abcg2/ABCG2 inhibition. Sub-toxic concentrations of the cannabinoids resensitized the overexpressing cell line to the cytotoxic effect of Abcg2/ABCG2 substrates, mitoxantrone and topotecan. This occurred in the absence of any effect on ABCG2 expression. Cannabinoids are novel Abcg2/ABCG2 inhibitors, reversing the Abcg2-mediated multidrug-resistant phenotype in vitro. This finding may have implications for the co-administration of cannabinoids with pharmaceuticals that are ABCG2 substrates.Keywords
This publication has 40 references indexed in Scilit:
- Cholesterol Potentiates ABCG2 Activity in a Heterologous Expression System: Improved in Vitro Model to Study Function of Human ABCG2The Journal of pharmacology and experimental therapeutics, 2007
- ??9-Tetrahydrocannabinol, 11-Hydroxy-??9-Tetrahydrocannabinol and 11-Nor-9-Carboxy-??9-Tetrahydrocannabinol in Human Plasma After Controlled Oral Administration of CannabinoidsTherapeutic Drug Monitoring, 2006
- Modulation of P‐glycoprotein activity by cannabinoid molecules in HK‐2 renal cellsBritish Journal of Pharmacology, 2006
- A pilot clinical study of Δ9-tetrahydrocannabinol in patients with recurrent glioblastoma multiformeBritish Journal of Cancer, 2006
- Characterization of P-glycoprotein Inhibition by Major Cannabinoids from MarijuanaJournal of Pharmacology and Experimental Therapeutics, 2006
- Enhanced exposure of phosphatidylserine in human gastric carcinoma cells overexpressing the half-size ABC transporter BCRP (ABCG2)Biochemical Journal, 2003
- Inhibitory effects of cannabinoid CB 1 receptor stimulation on tumor growth and metastatic spreading: actions on signals involved in angiogenesis and metastasisThe FASEB Journal, 2003
- Breast Cancer Resistance Protein Directly Confers SN-38 Resistance of Lung Cancer CellsBiochemical and Biophysical Research Communications, 2001
- Δ9‐Tetrahydrocannabinol induces apoptosis in human prostate PC‐3 cells via a receptor‐independent mechanismFEBS Letters, 1999
- Overexpression of a Transporter Gene in a Multidrug-Resistant Human Lung Cancer Cell LineScience, 1992